The U.S. Food and Drug Administration (FDA) has approved a new GLP-1 weight-loss pill from drugmaker Eli Lilly, the agency said on Wednesday.
The drug – Foundayo – is the second oral GLP-1 pill approved for sale in the U.S. after the agency approved Novo Nordisk's Wegovy pill in December 2025.
The once-a-day oral pill was approved for "adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight," Eli Lilly said.
Read more to find out how much the drug would cost.
Common antidepressant may help adults with long COVID: study
A recently released study suggests that fluvoxamine, a low‑cost and widely available antidepressant, "significantly improved fatigue and quality of life among adults with long COVID."
The study was co‑led by researchers at McMaster University, alongside those in Brazil and the United States, conducting a clinical trial with 399 adults with fatigue persisting 90 or more days after confirmed SARS-CoV-2 infection.
The results found that fluvoxamine "showed a significant reduction in fatigue compared with placebo at day 60," alongside "improv[ing] quality-of-life scores with high posterior probability."
Read more to find out about the results of the study.
— THE TOPIC —
One province is lowering the age of colorectal cancer screenings. Could more follow?
One province and one territory are taking steps to lower the screening age for colorectal cancer, with more probing a similar change.
Earlier this week, Prince Edward Island announced it's lowering the age to 45, with Nunavut confirming to Global News on Tuesday its plans to make the same change.
BC Cancer said in an email to Global News it is also investigating such an adjustment.
Read more to find out why the change has been made.
0 Komentar untuk "Health IQ: U.S. FDA approves a new weight loss pill"